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Patients’ satisfactiona b s t r a c t
Subject: Paediatric inﬂuenza is an unsolved public health problem, with high attack rates and spread
from children to the chronically ill. The nasal live attenuated inﬂuenza vaccine (LAIV) is an attractive
option for paediatric vaccination and provides good immunogenicity.
Methods: Interviewer-blinded analysis of a cohort of children vaccinated with LAIV versus matched
unvaccinated controls to assess the effectiveness, safety and tolerability of LAIV in routine paediatric care.
Results: In the fall of 2012, 146 children (median age 8.7 years, 63% males, 37% females) received LAIV
(131-single dose, 15 two-dose), among them 48% with intermittent to moderate persistent asthma. Inﬂu-
enza-like illness (ILI) was reported in 7/144 (5%) vaccinees compared to 33/144 (22%) matched controls,
yielding a vaccine effectiveness estimate of 79% (95% conﬁdence interval: 54–90%). Duration of ILI-epi-
sodes was on the average 4.0 days after LAIV versus 8.0 days in controls. Among vaccinees, 16/144
(11%) reported nasal congestion, 3/144 other side effects (e.g., 1 episode of bronchitis with urticaria
3 days post vaccination). All parents stated a desire for repeat inﬂuenza vaccination next season (4 with
trivalent intramuscular inﬂuenza vaccine, 140 with LAIV). LAIV administration had a mean acceptability
rating of 1.55 (1 = very good, 6 = unacceptable).
Conclusion: In routine administration in Germany, LAIV was highly effective and well-tolerated, resulting
in good patient satisfaction. Nasal LAIV offers a suitable way to increase paediatric inﬂuenza immuniza-
tion coverage.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Paediatric inﬂuenza remains an unsolved public health prob-
lem. Recent experience with seasonal (e.g., H3/N2) and pandemic
(e.g., H1/N1) inﬂuenza viruses have underscored the risk in sub-
jects without underlying chronic morbidity. Children have higher
attack rates than adults and spread the disease in the population,
exposing the chronically ill to additional risks. Also in Germany
during the 2012/13 inﬂuenza season, the attack rate of 5–14-year
old children was 12%, and paediatric ﬂu majorly contributed to
the overall burden of disease [Fig. 1; [1]]. Chronic diseases of the
airways such as bronchial asthma are established risk factors of
inﬂuenza; asthma was the leading underlying morbidity inpatients hospitalized for inﬂuenza during the H1N1 pandemic in
2009 [2,3]. According to the WHO, inﬂuenza immunization is the
most effective strategy for the prevention of inﬂuenza, and the
most cost-effective strategy to control the disease. Many scientiﬁc
committees recommend annual paediatric inﬂuenza immuniza-
tion. In Germany, inﬂuenza immunization is indicated for children,
adolescents and adults with an increased risk for inﬂuenza, e.g.,
chronic airway disease such as asthma and other obstructive lung
diseases. Weaknesses of humoral immunity in asthmatics has also
to be addressed [4]. For many years, intramuscular trivalent inﬂu-
enza vaccines (TIVs) have been available for children six month old
and older. Despite existing immunization recommendations and
the availability and reimbursement of inﬂuenza vaccines, the vast
majority of children do not receive them. Live attenuated inﬂuenza
vaccine (LAIV) is an attractive option for paediatric vaccination,
since it does not only offer a convenient route of administration,
but also induces good immunogenicity in young children as well.
Overall immunogenicity of LAIV in children is superior to unadju-
vanted TIVs [5–7]. In September 2012, Ann Arbor strain LAIV was
approved for use in Europe in 2–17 year old children. There are
Fig. 1. Inﬂuenza consultation incidence 2012/2013 season in Germany: calculated number of acute respiratory infections (ARI) presented to a physician/week and 100.000
age-speciﬁc population; y.o. = year old.
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tiveness, tolerability, and patients’ satisfaction under routine care
conditions.Methods
As part of routine paediatric care and according to German
immunization recommendations, 146 children were vaccinated
with LAIV in September–October 2012 (131 single-dose, 15 twice)
in a paediatric walk-in clinic with pneumological focus (12,000–
14,000 patient consultations/year, 1600 with chronic lung prob-
lems). Forty-eight percent of our vaccinees suffered from bronchial
asthma level 1-3 according to the Global Initiative on Asthma
(GINA) classiﬁcation (Table 1). This classiﬁcation distinguishes
grade 1 ‘‘intermittent asthma’’ (daytime symptoms <1 time a week,
asymptomatic between attacks, night time symptoms 62 times a
month) from grade 2 ‘‘mild persistent’’ (daytime symptoms >1
time a week but <1 time a day, attacks might affect activity, symp-
toms at night >2 times a month), from grade 3 ‘‘moderate persis-
tent’’ (daily symptoms, attacks affect activity, night time
symptoms >1 time a week), and from grade 4 (limited physical
activity, continuous daytime symptoms and frequent at night).
Concomitant therapy included inhaled betamimetics, inhaled ste-
roids, and/or montelukast (depending on the severity). Other indi-
cations for inﬂuenza immunization encompassed chronic
metabolic, allergic, neurologic, metabolic or cardio-pulmonary
disorders.Table 1
Features of the study population.
LAIV Controls
Age [median (range)] 8.7 years (2–17) 8.5 years (2–17)




Bronchial asthma [number (%)] 69 (47.9%) 69 (47.9%)
Asthma degree [median, (SD),
range]
2 (0.75); 1–3 2 (0.73); 1–3
No. of subjects with 1 LAIV dose 131 n.a.
No. of subjects with 2 LAIV doses 15 n.a.
No. of evaluated subjects 144 144
LAIV = live-attenuated inﬂuenza vaccine; % = percent(age); SD = standard deviation;
asthma degree according to Global Initiative on Asthma-classiﬁcation; n.a. = not
applicable.An independent epidemiologist matched every vaccinee with a
control of comparable demographic and medical background. All
vaccinees and 144 matched-controls underwent investigator-
blinded phone-interviews documenting all episodes of inﬂuenza-
like illness (ILI), cough, fever, pneumonia, common cold and
bronchitis in the 2012–2013 ﬂu season (1.11.2012-3.5.2013).
Inﬂuenza-like illness was deﬁned as a sudden onset of fever over
39 C with myalgia and respiratory symptoms (cough, sore throat).
No virological testing was performed. In a second independent
telephone interview and in order to evaluate safety and
tolerability, the parents of LAIV-immunized subjects were asked
by a different interviewer about adverse events within 10 days
after LAIV (nasal congestion, wheezing, cough, bronchitis, fever
as deﬁned as body temperature >38.5 C). Additionally, parents
were asked about their overall satisfaction with the nasal vaccine.
We also assessed their attitude towards an inﬂuenza immunization
in the next season, and if it was positive, whether they would
choose TIV or LAIV for their child.
Ahead of each interview, the interviewed subjects were asked
whether they accepted to participate, and that a refusal would
have no impact on the supplied paediatric care. The study was per-
formed in accordance with the declarations of Helsinki, Hong Kong,
and the German Drug Act. Local ethical committee approval was
obtained. For LAIV immunizations, participants, parents or guard-
ians provided written informed consent.
The distributions of categorical variables were compared be-
tween LAIV recipients and matched controls with a chi-square test
for two independent samples. A log binomial model was used to
estimate vaccine effectiveness which was deﬁned as one minus
the relative risk of ILI among LAIV recipients versus controls.Results
Clinical effectiveness
Two LAIV-immunized subjects moved away and were lost to
follow up. In the remaining group, inﬂuenza-like illness (ILI) was
reported in 7/144 (4.86%) vaccinees compared to 33/144 (22.9%)
matched controls (Table 2), yielding a vaccine effectiveness esti-
mate of 79% (95% conﬁdence interval: 54–90%). Duration of ILI-epi-
sodes was on average 4.0 days after LAIV versus 8.0 days in
controls. There was signiﬁcantly less spread of inﬂuenza in the
households of LAIV recipients: ILI episodes in seven family mem-
bers in seven households versus 79 ILI-affected family members
Table 2
Incidence of respiratory tract infections in LAIV recipients vs. unimmunized matched
controls in the winter season 2012/13.
LAIV Controls p =
ILI Episodes [total no. (% of affected
subjects)]
7 (4.86%) 33 (22.9%) 0.0001







ILI in household members [no. of affected
subjects (no. of households)]
7 (7) 79 (45) 0.0001
Common colds [no. of affected subjects
(no. of households)]
202 (117) 229 (127) 0.1000
1 episode (% of study arm) 66
(45.6%)
69 (47.9%)
2 episodes (% of study arm) 29
(20.0%)
37 (25.7%)
3 episodes (% of study arm) 13
(9.03%)
8 (5.55%)
4 episodes (% of study arm) 6 (4.17%) 5 (3.47%)
5 episodes (% of study arm) 3 (2.08%) 6 (4.17%)
6 episodes (% of study arm) 0 (0.00%) 2 (1.39%)
Pneumonia (no. of episodes (no. of
affected individuals)
5 (5) 18 (13) 0.0070
Otitis media [episodes (no. of affected
individuals)]
4 (4) 20 (18) 0.0019
LAIV = live-attenuated inﬂuenza vaccine; No. = number of affected vaccines;
% = percent; SD = standard deviation
M.A. Rose et al. / Trials in Vaccinology 2 (2013) 49–52 51in 45 control-households. There were no differences in the cumu-
lative incidence of common cold episodes between LAIV recipients
and controls; the majority of the children suffered from one to
three episodes. Pneumonia was observed in more than twice as
many controls as in LAIV immunized children (13 versus ﬁve)
and recurrent pneumonia occurred in unimmunized subjects only
(ﬁve children with two episodes, each). The same was observed for
otitis media; 18 unvaccinated controls experienced at least one
episode, compared to four LAIV recipients with one episode, each.
Safety, tolerability and parents’ satisfaction
Overall safety and tolerability of LAIV were excellent (Table 3).
Nasal obstruction was observed in 11% of LAIV recipients, lasting
for an average of three days. Other side effects of LAIV included
cough (2%), wheezing (0.7%) and bronchitis (1.4%). Fever was re-
ported in 3.5% of LAIV recipients. The only severe side effect was
an episode of urticaria three days post vaccination in association
with an airway infection.
LAIV administration had a mean acceptability rating of 1.55
(1 = very good, 6 = unacceptable). All parents (100%) reported a de-Table 3
LAIV in routine usage: Side effects and parents’ satisfaction.
Symptoms No. (%) Duration [median (SD), range]
Nasal obstruction 16
(11.1)
3.0 (8.56) days, 1.0–28
Cough 3
(2.13)
3.5 (0.87) days, 2.0-3.5
Wheezing 1
(0.69)
2.0 days (not applicable)
Fever 5
(3.47)
2.0 (0.89) days, 1.0–3.5
Bronchitis 2
(1.39)
1.5 (0.71) days, 1.0–2.0
Acceptability Ranking 1.5 (0.62), 1-4




Distribution: LAIV 140 (97.2%),
TIV 4 (2.3%)
LAIV = live-attenuated inﬂuenza vaccine; No. = number of affected vaccines;
% = percent; SD = standard deviation.sire for repeat inﬂuenza vaccination for the next season (four with
TIV, 140 with LAIV) (see Table 3).Discussion
Despite the high paediatric inﬂuenza morbidity and existing
immunization recommendations, coverage rates are inacceptable
low. A recent survey performed in the general paediatric popula-
tion in Germany from July 2012 through March 2013 reported an
inﬂuenza immunization coverage of 1.8% in one year old children
to 6% in ﬁve year olds [API survey 2012/13; unpublished data].
During the inﬂuenza wave of 2012/2013 in Germany, infants and
preschool children had the highest burden of disease [1]. Estab-
lished TIVs have the disadvantages of an -especially in young chil-
dren- relatively low immunogenicity and are unattractive for
children as the mean potentially painful injections [8]. Facing that
infants and preschool children carry the highest burden of inﬂu-
enza among all age groups, all attempts should be made to improve
protection from inﬂuenza especially in the young. Our study dem-
onstrates the good effectiveness of LAIV in routine conditions of
79% against ILI.
As with all paediatric immunization trials, placebo-controlled
designs are hard to perform. In contrast, uncontrolled open pro-
spective studies often present biases associated with different
expectations and perceptions of vaccinees and their guardians as
to protection from the preventable infection (placebo effects).
Our study design controlled for these biases by assessing LAIV as
part of routine care in all children vaccinated with LAIV at a large
paediatric centre during autumn of 2012. Besides proven immuno-
genicity and safety of paediatric inﬂuenza immunization strategies,
practical aspects such as routes and feasibility of administration
and the acceptance and willingness of the parents to have their
child immunized play a major role [9]. Additionally, experiencing
inﬂuenza-like health outcomes after and despite of inﬂuenza
immunization often has a negative impact on attitudes towards
upcoming seasonal inﬂuenza immunization. In our study, the vast
majority of parents declared good or very good satisfaction with
nasal LAIV immunization, 100% wished to have their children vac-
cinated against inﬂuenza in the future, and among them 97% with
LAIV. In accordance with published data, general safety was good
with side effects being limited to temporary nasal obstruction in
11% of our LAIV recipients. The only severe adverse event was an
episode of bronchitis with urticaria three days after LAIV in one
vaccinee. This event is known from literature to occur at a rate of
5-8/10,000 vaccinees [10]. However, since the affected subject suf-
fered from an airway infections in parallel, this might have been
simply coincident and due to an acute infection such as myco-
plasma pneumoniae, which is often associated with urticaria.
In licensure studies, LAIV has been associated with an increase
in wheezing, resulting in age restrictions (not under age 2) and
warnings as to its use in severe asthma or acute obstructive airway
symptoms, since the expected mucosal reaction might favor bron-
chial obstruction [11]. Various post-licensure observational trials
from health insurance data on LAIV usage in children with asth-
ma/recurrent wheeze could not conﬁrm these risk signals. From
2007 until 2009, no differences of hospitalizations or emergency
department consultations within 42 days after LAIV or TIV could
be detected [12]. Some trials even detected reductions in wheezing
and viral illness after LAIV [13,14]. Remarkably, a recent analysis
from 2009-2010 revealed that TIV immunized children had to un-
dergo emergency treatment for asthma or acute bronchitis twice as
often (4.5% after LAIV versus 9.5% after TIV); they consistently suf-
fered more often from airway complaints as well [15]. The authors
discussed this observation not only on the basis of a higher immu-
nogenicity of LAIV, but also postulated a preferred TIV usage in the
52 M.A. Rose et al. / Trials in Vaccinology 2 (2013) 49–52chronically ill due to warnings against LAIV immunization in chil-
dren with chronic airway disease, exposing the per se endangered
patients to even higher risks of inﬂuenza.
The major strength of our study is that it reﬂects real world use.
Our observational non-randomized observational design made this
possible but could have resulted in comparing groups with differ-
ent health status. It is unlikely that the nonrandomized design was
responsible for the different outcomes observed in vaccinees ver-
sus controls. However, comparisons with our matched controls at-
tempted to control for such bias. With regard to the exploratory
character of our study and the lack of a formal hypothesis testing,
no corrections were made for multiple comparisons. Nonetheless,
recall bias might still have an impact on the results, potentially
resulting in misclassiﬁcation of outcomes.
In clinical routine, given the warnings against LAIV use in severe
asthma, TIV-vaccinees might have a poorer health status compared
to LAIV recipients. Matching unimmunized controls from other
sources (e.g., hospital/emergency room data-base) might have
the bias of the unvaccinated having poorer access to health care
overall [15,16]. Our study design controlled also for such bias by
matching patients from the same paediatric centre with identical
social background and access to health care.
Conclusion
In routine paediatric care in Germany, LAIV was highly effective
and well-tolerated, resulting in good patient/parent satisfaction.
Nasal LAIV offers a suitable way to increase paediatric inﬂuenza
immunization coverage.
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